Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 59

Related Articles by Review for PubMed (Select 18759509)

1.

Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis.

Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Deveaugh-Geiss A, Krebs EE, Lohr KN.

Drug Saf. 2008;31(10):851-65. Review.

PMID:
18759509
2.

The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis.

Gartlehner G, Thaler K, Hansen RA, Gaynes BN.

Drug Saf. 2009;32(12):1159-73. doi: 10.2165/11318930-000000000-00000. Review.

PMID:
19916583
3.

Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.

Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN.

Ann Intern Med. 2008 Nov 18;149(10):734-50. Review.

PMID:
19017592
4.

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.

Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS.

Ann Intern Med. 2005 Sep 20;143(6):415-26. Review.

PMID:
16172440
5.

Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis.

Reichenpfader U, Gartlehner G, Morgan LC, Greenblatt A, Nussbaumer B, Hansen RA, Van Noord M, Lux L, Gaynes BN.

Drug Saf. 2014 Jan;37(1):19-31. doi: 10.1007/s40264-013-0129-4. Review.

PMID:
24338044
6.

Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis.

Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, Mager U, Thieda P, Gaynes BN, Wilkins T, Strobelberger M, Lloyd S, Reichenpfader U, Lohr KN.

Ann Intern Med. 2011 Dec 6;155(11):772-85. doi: 10.7326/0003-4819-155-11-201112060-00009. Review.

PMID:
22147715
7.

Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis.

Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA; MANGA (Meta-Analysis of New Generation Antidepressants) Study Group.

CNS Drugs. 2010 Jan;24(1):35-53. doi: 10.2165/11319480-000000000-00000. Review.

PMID:
20030418
8.

Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine.

Maneeton N, Maneeton B, Eurviriyanukul K, Srisurapanont M.

Drug Des Devel Ther. 2013 Sep 27;7:1053-62. doi: 10.2147/DDDT.S46849. eCollection 2013. Review.

9.

Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis.

Nussbaumer B, Morgan LC, Reichenpfader U, Greenblatt A, Hansen RA, Van Noord M, Lux L, Gaynes BN, Gartlehner G.

CNS Drugs. 2014 Aug;28(8):699-712. doi: 10.1007/s40263-014-0169-z. Review.

PMID:
24794101
10.

Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review [Internet].

Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux LJ, Van Noord M, Mager U, Gaynes BN, Thieda P, Strobelberger M, Lloyd S, Reichenpfader U, Lohr KN.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Dec.

11.

Agomelatine versus other antidepressive agents for major depression.

Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M.

Cochrane Database Syst Rev. 2013 Dec 17;12:CD008851. doi: 10.1002/14651858.CD008851.pub2. Review.

PMID:
24343836
12.

Second-generation antidepressants for seasonal affective disorder.

Thaler K, Delivuk M, Chapman A, Gaynes BN, Kaminski A, Gartlehner G.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD008591. doi: 10.1002/14651858.CD008591.pub2. Review.

PMID:
22161433
13.

Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review.

Thaler KJ, Morgan LC, Van Noord M, Gaynes BN, Hansen RA, Lux LJ, Krebs EE, Lohr KN, Gartlehner G.

Depress Anxiety. 2012 Jun;29(6):495-505. doi: 10.1002/da.21951. Epub 2012 May 2. Review.

PMID:
22553134
14.

[Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].

Favré P.

Encephale. 2012 Feb;38(1):86-96. doi: 10.1016/j.encep.2011.11.003. Epub 2011 Dec 10. Review. French.

PMID:
22381728
15.

Duloxetine versus other anti-depressive agents for depression.

Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD006533. doi: 10.1002/14651858.CD006533.pub2. Review.

16.

Mirtazapine versus other antidepressive agents for depression.

Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD006528. doi: 10.1002/14651858.CD006528.pub2. Review.

17.

Newer generation antidepressants for depressive disorders in children and adolescents.

Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD004851. doi: 10.1002/14651858.CD004851.pub3. Review.

PMID:
23152227
18.

Fluoxetine versus other types of pharmacotherapy for depression.

Magni LR, Purgato M, Gastaldon C, Papola D, Furukawa TA, Cipriani A, Barbui C.

Cochrane Database Syst Rev. 2013 Jul 17;7:CD004185. Review.

PMID:
24353997
19.

Fluoxetine versus other types of pharmacotherapy for depression.

Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, Malvini L, Barbui C.

Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004185. Review. Update in: Cochrane Database Syst Rev. 2013;7:CD004185.

20.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk